Results 91 to 100 of about 32,014 (250)
Cancer pain: current practice and emerging targets
Cancer pain (CP) arises from a complex interplay between the tumour and its microenvironment. Many patients experience a mixed pain phenotype that encompasses nociceptive, neuropathic and neuroinflammatory mechanisms, and vary across tumour type and disease stage. Despite decades of intensive research, the mainstay of cancer pain treatment is still non‐
Yi Ye +5 more
wiley +1 more source
MAPK Inhibitor‐Tolerant Persister Cells in Melanoma: Mechanisms and Therapeutic Vulnerabilities
Melanoma response to MAPK inhibition progresses from drug‐sensitive cells to drug‐tolerant persister states, which enable survival through adaptive signaling, metabolic rewiring, and phenotypic plasticity. These persister cells serve as an intermediate reservoir from which resistant tumors ultimately emerge. ABSTRACT Though major advancements have been
Bhoomi Shah +3 more
wiley +1 more source
Gasdermin‐Mediated Pyroptosis: Novel Strategies Against Colorectal Cancer
Pyroptosis is a double‐edged sword in colorectal cancer (CRC): chronic low‐grade pyroptosis promotes tumor progression, whereas acute induction of pyroptosis in cancer cells triggers antitumor immunity and enhances therapeutic response. Targeting gasdermin‐mediated pyroptosis represents a promising strategy for CRC treatment.
Kaibo Guo +6 more
wiley +1 more source
Schematic overview of progression from differentiated thyroid carcinoma (DTC) to anaplastic thyroid carcinoma (ATC). ATC primarily develops via two pathways: the BRAF p.V600E‐mutated papillary thyroid carcinoma (PTC) pathway and the RAS‐mutated pathway. The origin and progression of BRAF/RAS‐wildtype ATC remain unclear.
Toru Odate, Tetsuo Kondo
wiley +1 more source
Ketogenic diet and β‐hydroxybutyrate (β‐HB) suppress bladder cancer growth through direct anti‐tumor mechanisms and enhance anti‐PD‐L1 immunotherapy efficacy. β‐HB upregulates PD‐L1 via JAK2‐STAT3 activation and remodels the tumor immune microenvironment, sensitizing tumors to immune checkpoint blockade. ABSTRACT The limited clinical efficacy of immune
Yuan Zeng +6 more
wiley +1 more source
Primary mucosal melanoma: A case report
Malignant melanoma is an aggressive malignancy of melanocytes affecting both skin and mucosa. Primary oral melanoma occurs 0.2-8% of all melanomas and accounts for 0.5% of all oral malignancies.
Fereshteh Baghai +4 more
doaj
Superficial Ewing Sarcoma of the Rectum: A Case Report and the Utility of Molecular Diagnostics
ABSTRACT Ewing sarcoma is an undifferentiated small round cell sarcoma that most commonly presents as a malignant bone tumor in pediatric and young adult patients. The diagnosis is typically confirmed by molecular genetic identification of a fusion protein, most commonly involving members of the FET and ETS gene families.
Jessica L. Muldoon +3 more
wiley +1 more source
Melanoma In Situ of the Hard Palate
Mucosal melanoma of the oral cavity is rare and highly aggressive, thought to represent less than 1% of melanomas. Within this subgroup, melanoma in situ has been rarely described.
Teresa G. Vos MD +2 more
doaj +1 more source
A Curious Case of Primary Gastric Mucosal Melanoma
Malignant melanoma is a neoplasm of melanin-producing cells predominantly of cutaneous origin, which uncommonly develops within gut mucosa. We present the case of a 58-year-old woman with complaints of abdominal pain, loss of appetite and weight ...
Zahabia Sohail +3 more
doaj +1 more source
ABSTRACT Introduction Preferentially expressed antigen in melanoma (PRAME) immunohistochemistry helps distinguish non‐acral melanocytic lesions, but few studies have addressed its value in acral lesions. We aimed to identify an optimal PRAME cut‐off score to differentiate acral melanoma (AM) from acral melanocytic nevi (AMN).
Kritsada Phatcharamaneepakorn +4 more
wiley +1 more source

